Form 4: Gilead Sciences Executive Deborah H. Telman Reports Stock Transactions
SEC Form 4 Filing
Deborah H. Telman, EVP at Gilead Sciences, reported the acquisition of 515 common stock units and the disposal of 187 common stock units on January 25, 2025.
Summary
- Deborah H. Telman, an Executive Vice President at Gilead Sciences, filed a Form 4 detailing changes in her beneficial ownership of company stock.
- On January 25, 2025, Ms. Telman acquired 515 shares of common stock through the vesting of restricted stock units.
- On the same day, she disposed of 187 shares of common stock at a price of $93.07 per share.
- Following these transactions, Ms. Telman directly owns 21,640 shares of Gilead Sciences common stock.
- She also holds 27,879 restricted stock units, which vest over a four-year period.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing detailing stock transactions by an executive, which is neither positive nor negative in itself. It is a neutral event.
Industry Context
This is a routine filing related to executive stock transactions and is common practice for publicly traded companies. It provides transparency into the trading activities of company insiders.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, such as Gilead Sciences, and are required by the SEC to ensure transparency of insider trading.
- Similar filings are made by executives at comparable companies like Amgen (AMGN) and Biogen (BIIB) when they engage in stock transactions.
- The vesting schedule of the restricted stock units, with 25% vesting on the first anniversary and the remainder quarterly, is a common practice in the biotech industry for executive compensation.
Stakeholder Impact
- The stock transactions have a minimal impact on shareholders as they are part of routine executive compensation and do not indicate a significant change in the company's outlook.
Key Dates
| Date | Description |
|---|---|
| 01/25/2025 | Date of stock acquisition and disposal by Deborah H. Telman. |
| 01/27/2025 | Date the Form 4 was signed. |
Keywords
Gilead Sciences, stock transaction, Form 4, insider trading, restricted stock units, executive compensation, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.